Apogee Therapeutics, Inc. (APGE)

NGM – Real Time Price. Currency in USD

134.55

-0.14 (-0.10%)

At close: Aug 12, 2026, 4:00 PM EDT

134.55

0.00 (0.00%)

After-hours: Aug 12, 2026, 4:10 PM EDT

12.08.2026

This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

10.08.2026

Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates

AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive 16-week Phase 2 APEX Part B induction dose optimization results support planned advancement of zumilokibart into Phase 3 development in moderate-to-severe atopic dermatitis this year SAN FRANCISCO and BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today reported second quarter 2026 financial results, recent corporate updates and pipeline progress. "The second quarter marked a transformational period for Apogee," said Michael Henderson, M.D.

Videos

No Data

There is no data to display

Press releases

10.08.2026

Apogee Therapeutics, Inc. (APGE)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Apogee Therapeutics, Inc. (APGE)

This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates

Videos

No Data

Press releases

Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates

This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates

Videos

No Data

Press releases

Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates

Search stocks

Apogee Therapeutics, Inc. (APGE)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Apogee Therapeutics, Inc. (APGE)

This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates

Videos

No Data

Press releases

Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates

This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates

Videos

No Data

Press releases

Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates